Australia's most trusted
source of pharma news
Tuesday, 18 November 2025
Posted 18 November 2025 AM
MSD is buying Cidara Therapeutics and its preventive antiviral biologic for influenza in a deal worth US$9.2 billion.
Johnson & Johnson had been working with San Diego-based Cidara on the antiviral, CD388, after paying US$27 million up front in 2021, plus a milestone payment, but then backed out of the research, and Cidara reacquired the candidate in 2024.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.